Feb 10, 2023 | Press Releases
MARLBOROUGH, Mass., Feb. 10, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...
Jan 25, 2023 | Press Releases
MARLBOROUGH, Mass., Jan. 25, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...
Jan 6, 2023 | Press Releases
MARLBOROUGH, Mass., Jan. 6, 2023 — Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that...
Jan 6, 2023 | Press Releases
MARLBOROUGH, Mass., Jan. 6, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced their clinical development partner, AgonOx, Inc. has received confirmation from the FDA that their planned Phase 1 clinical trial in patients with advanced solid tumors...
Dec 21, 2022 | Press Releases
MARLBOROUGH, Mass., Dec. 21, 2022 — Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company...
